Paper42852008PubMed
Geno-guided targeting of ferroptosis: a multi-layered network to overcome radioresistance in lung cancer.
Sang S and 6 others. Front Cell Dev Biol, 2026.
Cite this record
ConductScience Library. Geno-guided targeting of ferroptosis: a multi-layered network to overcome radioresistance in lung cancer. Papers, record 42852008. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42852008
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Geno-guided targeting of ferroptosis: a multi-layered network to overcome radioresistance in lung cancer.
- Journal
- Front Cell Dev Biol
- Year
- 2026
- Publication types
- Journal Article, Review
- Revised in PubMed
- 2026-10-10
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References172
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39832721 | SCARB1 links cholesterol metabolism-mediated ferroptosis inhibition to radioresistance in tumor cells. | J Adv Res | 2025 | https://conductscience.org/library/papers/39832721 | PubMed |
| 2 | 41476754 | Tumor lysate-cloaked CuMOF-sorafenib nanoassembler: A synergistic cuproptosis-ferroptosis nanoweapon against tumors. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41476754 | PubMed |
| 3 | 39243710 | Cu0-based nanoparticles boost anti-tumor efficacy via synergy of cuproptosis and ferroptosis enhanced by cuproptosis-induced glutathione synthesis disorder. | Colloids Surf B Biointerfaces | 2025 | https://conductscience.org/library/papers/39243710 | PubMed |
| 4 | 39871626 | Downregulation of AATK enhances susceptibility to ferroptosis by promoting endosome recycling in gefitinib-resistant lung cancer cells. | J Pathol | 2025 | https://conductscience.org/library/papers/39871626 | PubMed |
| 5 | 31899616 | Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis Inducers. | ACS Chem Biol | 2020 | https://conductscience.org/library/papers/31899616 | PubMed |
| 6 | 37939712 | Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma. | Cell Rep Med | 2023 | https://conductscience.org/library/papers/37939712 | PubMed |
| 7 | 38997257 | Glucose-6-phosphate dehydrogenase maintains redox homeostasis and biosynthesis in LKB1-deficient KRAS-driven lung cancer. | Nat Commun | 2024 | https://conductscience.org/library/papers/38997257 | PubMed |
| 8 | 36119826 | Pan-cancer profiles of the cuproptosis gene set. | Am J Cancer Res | 2022 | https://conductscience.org/library/papers/36119826 | PubMed |
| 9 | 38266782 | OTUB1 Targets CHK1 for Deubiquitination and Stabilization to Facilitate Lung Cancer Progression and Radioresistance. | Int J Radiat Oncol Biol Phys | 2024 | https://conductscience.org/library/papers/38266782 | PubMed |
| 10 | 34795058 | The ubiquitin E3 ligase FBXO22 degrades PD-L1 and sensitizes cancer cells to DNA damage. | Proc Natl Acad Sci U S A | 2021 | https://conductscience.org/library/papers/34795058 | PubMed |
| 11 | 33781891 | Epigenetic silencing of GCH1promotes hepatocellular carcinoma growth by activating superoxide anion-mediated ASK1/p38 signaling via inhibiting tetrahydrobiopterin de novo biosynthesis. | Free Radic Biol Med | 2021 | https://conductscience.org/library/papers/33781891 | PubMed |
| 12 | 39895264 | Harnessing an MMP-Independent NIR Probe Unveiling the Different Mitochondrial Cristae Changes during Mitophagy and Ferroptosis under STED Microscopy. | Anal Chem | 2025 | https://conductscience.org/library/papers/39895264 | PubMed |
| 13 | 38387144 | Involvement of GSTP1 in low dose radiation-induced apoptosis in GM12878 cells. | Ecotoxicol Environ Saf | 2024 | https://conductscience.org/library/papers/38387144 | PubMed |
| 14 | 38055636 | Nanointegrative In Situ Reprogramming of Tumor-Intrinsic Lipid Droplet Biogenesis for Low-Dose Radiation-Activated Ferroptosis Immunotherapy. | ACS Nano | 2023 | https://conductscience.org/library/papers/38055636 | PubMed |
| 15 | 33927351 | Ferroptosis as a mechanism to mediate p53 function in tumor radiosensitivity. | Oncogene | 2021 | https://conductscience.org/library/papers/33927351 | PubMed |
| 16 | 41750617 | Inducing Ferroptosis: Sensitization Strategy for Radiotherapy and Its Application. | Antioxidants (Basel) | 2026 | https://conductscience.org/library/papers/41750617 | PubMed |
| 17 | 41481031 | Albumin Nanoparticles Co-Loaded with Dual Drugs for Enhanced Ferroptosis-Based Cancer Therapy through Modulating Cholesterol Metabolism. | ACS Nano | 2026 | https://conductscience.org/library/papers/41481031 | PubMed |
| 18 | 29249655 | The PLAG1-GDH1 Axis Promotes Anoikis Resistance and Tumor Metastasis through CamKK2-AMPK Signaling in LKB1-Deficient Lung Cancer. | Mol Cell | 2018 | https://conductscience.org/library/papers/29249655 | PubMed |
| 19 | 40914022 | Engineering ferroptosis radiosensitizer for SPARC-targeted degradation: A strategy to reverse radioresistant non-small cell lung cancer. | Biomaterials | 2026 | https://conductscience.org/library/papers/40914022 | PubMed |
| 20 | 26403645 | Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. | Hepatology | 2016 | https://conductscience.org/library/papers/26403645 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42852008
GET https://conductscience.org/api/papers/v1/42852008/references?page=2